Breast cancer (BC) is a multifaceted disease characterized by distinct molecular subtypes
and varying responses to treatment. In BC, the phosphatidylinositol 3-kinase (PI3K) pathway …

Introduction Allosteric drugs are advantageous. However, they still face hurdles, including
identification of allosteric sites that will effectively alter the active site. Current strategies …

Somatic alterations in the oncogenic kinase AKT1 have been identified in a broad spectrum
of solid tumours. The most common AKT1 alteration replaces Glu17 with Lys (E17K) in the …

The H1047R mutation of PIK3CA is highly prevalent in breast cancers and other solid
tumors. Selectively targeting PI3KαH1047R over PI3KαWT is crucial due to the role that …

Tumor genomic profiling is increasingly seen as a prerequisite to guide the treatment of
patients with cancer. To explore the value of whole-genome sequencing (WGS) in …

Although anti-HER2 therapy has made significant strides in reducing metastasis and relapse
in HER2-positive breast cancer, resistance to agents like trastuzumab, pertuzumab, and …

The dysregulation of the phosphatidylinositol-3-kinase (PI3K) pathway can lead to
uncontrolled cellular growth and tumorigenesis. Targeting PI3K and its downstream …

mTOR plays a crucial role in PI3K/AKT/mTOR signaling. We hypothesized that mTOR
activation mechanisms driving oncogenesis can advise effective therapeutic designs. To test …

PIK3CA, which encodes the p110α catalytic subunit of PI 3-kinase alpha (PI3Kα), is one of
the most frequently genetically activated kinases in solid tumors. In two back-to-back papers …

Background Sorafenib (SFN) is the first-line medicine for advanced hepatocellular
carcinoma (HCC). However, Sorafenib resistance is a main challenge of therapeutic …